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Abstract
Caspase-9 is a component of the apoptosome that mediates cell death following release of cytochrome c from
mitochondria. Inhibition of Caspase-9 with a dominant negative construct (Casp9DN) blocks apoptosome function,
promotes viability and has been implicated in carcinogenesis. Inhibition of the apoptosome in vitro impairs mitochondrial
function and promotes mitophagy. To examine whether inhibition of the apoptosome would enhance mitophagy and
promote oncogenesis in vivo, transgenic mice were generated that express Casp9DN in the T cell lineage. The effects of
Casp9DN on thymocyte viability, mitophagy and thymic tumor formation were examined. In primary thymocytes, Casp9DN
delayed dexamethasone (Dex)-induced cell death, altered mitochondrial structure, and decreased oxidant production.
Transmission electron microscopy (TEM) revealed that inhibition of the apoptosome resulted in structurally abnormal
mitochondria that in some cases were engulfed by double-membrane structures resembling autophagosomes. Consistent
with mitochondria being engulfed by autophagosomes (mitophagy), confocal microscopy showed colocalization of LC3-
GFP and mitochondria. However, Casp9DN did not significantly accelerate T-cell lymphoma alone, or in combination with
Lck-Bax38/1, or with Beclin 1+/2 mice, two tumor-prone strains in which altered mitochondrial function has been
implicated in promoting tumor development. In addition, heterozygous disruption of Beclin 1 had no effect on T-cell
lymphoma formation in Lck-Bax38/1 mice. Further studies showed that Beclin 1 levels had no effect on Casp9DN-induced
loss of mitochondrial function. These results demonstrate that neither inhibition of apoptosome function nor Beclin 1
haploinsufficiency accelerate T-cell lymphoma development in mice.
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Introduction
Apoptosis is a highly conserved cell death pathway that regulates
tissue homeostasis and normal development. Bcl-2 family members
are critical regulators of the apoptosis pathway. The Bcl-2 family can
be classified into pro-apoptotic members which includes multi-
domain members (Bax,Bak) and BH-3 only members(Bim, Bid), and
anti-apoptotic members (Bcl-2, Bcl-xL) [1]. The Bcl-2 family
primarily regulates apoptosis through their effects on the mitochon-
drial outer membrane permeabilization (MOMP). Bax and Bak form
a multimeric complex that mediates the release of cytochrome c,
Smac/Diablo, and other factors from the intermembrane space of
mitochondria. In cytosol, cytochrome c binds to Apaf-1 and pro-
Caspase-9 forming the apoptosome and activating Caspase-9. This
initiator Caspase activates downstream effector Caspases such as
Caspase 3/7 that lead to apoptotic cell death. In contrast to Bcl-2,
IAP family proteins act downstream of mitochondrial permeabiliza-
tion as direct inhibitors of Caspase function.
Alterations in apoptosis have been associated with cancer as first
illustrated by the overexpression of Bcl-2 in B-cell lymphoma in
both human and murine models [2,3]. Similarly, mutations in Bax
and Bim have been found in multiple tumors and can accelerate
oncogenesis in murine models [4–7]. Alternatively, Bcl-2 family
members can paradoxically regulate oncogenesis as illustrated by
Bax overexpression increasing T-cell lymphoma (Lck-Bax38/1)
[8,9]. Downstream regulators of apoptosis such as Apaf-1,
Caspase-9 and IAP family members have also been examined in
oncogenesis. Reduced protein levels of Apaf-1 or Caspase-9 or
elevated expression of IAP family members have been found in a
variety of cancer cell lines [10–12] and primary tumor biopsy
samples [13–15]. Recent clinical studies report that proteins
involved in apoptosome function may provide prognostic
information. For example, patients with AML in which the tumor
cells express high XIAP levels have reduced survival compared to
controls [10]. Similarly, low levels of Apaf-1 were associated with
decreased survival in patients with CLL [15].
In mouse studies, Apaf-1 and Caspase-9 deficient mouse
embryonic fibroblasts had increased myc-induced transformation
relative to control cells [11]. However, Apaf-1 or Caspase-9
deficient hematopoietic cells fail to show accelerated myc-induced
lymphomagenesis [16]. Similarly, a dominant-negative form of
Caspase-9 (Casp9DN) interfered with apoptosome function but was
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However, whether apoptosome inhibition would accelerate onco-
genesis outside the context of overexpression of myc is unknown.
Autophagy is an evolutionarily conserved lysosome degradation
pathway that maintains energy homeostasis and mediates cellular
adaptation in response to stress. Defects in the autophagy pathway
have recently been associated with cancer formation. Numerous
studies suggest that Beclin 1, a rate-limiting autophagy protein, is a
haploinsufficient tumor suppressor gene. Beclin 1 is monoalleli-
cally deleted in 40–75% of cases of human ovarian, breast, and
prostate cancers [18]. Heterozygous disruption of Beclin 1
increased the incidence of sporadic malignancies in mice,
including lymphoma [19,20]. Interestingly, tumor formation in
Beclin 1+/2 does not involve complete loss of the Beclin 1 protein
or gene. Therefore Beclin 1 is considered a haploinsufficient tumor
suppressor gene [20]. While the exact mechanisms by which
defects in autophagy promote cancer are not known, one model is
that inefficient clearance of dysfunctional proteins and/or
mitochondria increases oxidative stress and promotes DNA
damage and genetic instability [21–23].
Selective elimination of dysfunctional mitochondria by the
autophagy pathway is termed mitophagy. While the signals that
control and regulate mitophagy are largely unknown, two recent
studies report that inhibition of the apoptosome may result in
mitophagy. Molecular or chemical inhibition of Caspase activity
combined with an apoptotic signal, results in cells with impaired
mitochondrial function and reliance on glycolysis for cell survival
[24]. Overexpression of glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) elevates ATP levels and enhances mitophagy in
those cells [25]. Whether Beclin 1 plays a rate-limiting role in the
activation of mitophagy following MOMP is not clear. Further-
more, the in vivo importance of mitophagy in tumorigenesis
remains unknown and requires further investigation.
In summary, while numerous studies have suggested that
inhibition of the apoptosome may promote mitophagy as well as
oncogenesis, this hypothesis has not been rigorously tested in an
animal model. To directly test this model, we have developed mice
that express a dominant negative form of Caspase-9 in the T cell
lineage (Lck-Casp9DN). Herein we demonstrate that apoptosome
activity is effectively inhibited and mitophagy increases in
thymocytes from these mice. To examine the oncogenic potential
of this transgenic line, we determined the rate of tumor formation
in Lck-Casp9DN mice crossed to Lck-Bax38/1 and Beclin 1+/2
mice, two tumor-prone strains in which altered mitochondrial
function has been implicated in oncogenesis.
Results
Casp9DN delays cell death and impairs apoptotic
pathway in primary thymocytes
In order to examine the effect of Caspase-9 inhibition on T cell
death and lymphoma formation in vivo, transgenic mice were
generated using the Lck promoter that directs expression in
mature and immature T cells. A high expressing transgenic line
was identified and shown to express high levels of Casp9DN with
marked inhibition of Caspase-3 and PARP cleavage (Figure 1A
and 1B). To determine if Casp9DN delays lymphoid cell death,
cell viability was measured in primary thymocytes isolated from
wild type or Lck-Casp9DN transgenic mice following Dex
treatment (Figure 1C). Q-VD-OPh, a broad-spectrum inhibitor
of Caspase activity, was used as a positive control. Expression of
Casp9DN markedly reduced cell death following Dex treatment
almost as effectively as Q-VD-OPh. These results demonstrate
that Casp9DN expression significantly delays in vitro apoptotic cell
death in thymocytes.
The effect of Casp9DN on thymic cellularity and
proliferation
Previous studies suggest that Caspase cascade blockage results in
cell cycle arrest following Q-VD-OPh treatment in FL5 cells [24].
Thymic cellularity is markedly reduced and thymocyte prolifer-
ation is increased in Lck-Bax38/1 transgenic mice [8]. To
determine the effect of Casp9DN on thymus size and thymocyte
proliferation, thymocytes were harvested, counted and analyzed
for cell proliferation using DNA content analysis for both control
and Lck-Bax38/1 mice. Surprisingly, Casp9DN had no effect on
Figure 1. Casp9DN expression inhibits Dex-induced apoptotic cell death in primary thymocytes. A) Whole cell lysates were prepared
from primary thymocytes from wild type (WT) or Lck-Caspase-9DN (Lck-Casp9DN) transgenic mice as described under ‘‘Experimental Procedures’’.
Immunoblots for pro-Caspase-9 (pro-C9) and actin as a loading control are shown. B) Primary thymocytes were isolated from mice of the indicated
genotypes, and treated with or without Dex (1 mM) for 6 h. Immunoblots for Caspase-3 (C3), PARP, and actin as a loading control are shown. C)
Isolated thymocytes from mice of the indicated genotypes were treated with Dex (1mM). Q-VD-OPh (50 mM), a pan Caspases inhibitor, was used as
positive control for Caspase inhibition. Cell viability was determined over time by using a Guava flow cytometer and Viacount reagent. The means 6
SD for at least duplicate samples are shown.
doi:10.1371/journal.pone.0019786.g001
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(Figure 2A). If Casp9DN effectively blocked apoptosis in vivo,w e
hypothesized that cellularity would be increased in Lck-Casp9DN
transgenic mice. However, for both control and Lck-Bax38/1
mice, thymic cellularity was unaffected by Casp9DN expression
(Figure 2B). These results suggest Casp9DN expression had little
effect on the survival of thymocytes in vivo with or without Bax
expression. However, these results examining whole organ
homeostasis, do not rule out the possibility that a small fraction
of cells are protected from cell death for a short period of time
following a death signal.
Isolated thymocytes from Lck-Casp9DN transgenic mice
have reduced ROS levels
Previous studies show that Casp9DN or Q-VD-OPh treatment
reduced reactive oxygen species (ROS) levels following an
apoptotic signal [24]. To determine if Casp9DN affects oxidative
stress in vivo, dihydroethidium (DHE) and MitoSOX Red staining
were performed on primary thymocytes with or without Dex
treatment. Under these conditions, control cells were treated with
Q-VD-OPh so that both chemical and molecular inhibitors of
Caspases were examined. Cultured thymocytes die spontaneously
in culture and the death is greatly accelerated by Dex treatment.
Casp9DN expression or Q-VD-OPh treatment showed a large
fraction of cells with reduced DHE staining that was not detected
in cells in which caspase activity is not inhibited (Figure 3A). These
results were supported by also staining cells with MitoSOX Red,
another redox-sensitive reagent that is concentrated in the
mitochondria [26]. Casp9DN expressing and Q-VD-OPh treated
thymocytes were found to have reduced MitoSOX Red fluores-
cence indicative of reduced oxidation (Figure 3B). Finally, to
determine if these redox changes occur in vivo, DHE staining of
freshly isolated thymocytes from Lck-Casp9DN transgenic mice
also demonstrated a significant population of cells with reduced
DHE staining (Figure 3C).
Caspase inhibition alters mitochondrial morphology in
primary thymocytes and FL5 cells
To determine the effect of Caspase inhibition on mitochondrial
morphology, TEM was performed on thymocytes following
various treatment conditions. In the absence of Caspase inhibition,
all viable thymocytes had mitochondria with well-defined cristae,
intact and clear double membranes, homogenous density and
cylindrical shape. In contrast, thymocytes expressing Casp9DN or
treated with Q-VD-OPh frequently had abnormal mitochondria
with disorganized cristae, a discontinuous double membrane,
decreased electron density and an increase in the minor axis
consistent with mitochondrial swelling (Figure 4A). Importantly,
individual cells had uniform mitochondria that were either all
classified as normal or abnormal. Using these criteria, quantitative
analysis after 4 hours of Dex treatment showed that Casp9DN
expression or Q-VD-OPh treatment markedly increased the
average number of abnormal mitochondria per cell and the
percentage of viable cells with abnormal mitochondria was about
50% (Figure 4B). Of note, this percentage is comparable to the
level of protection by Caspase inhibition (Figure 1C) and to the
percentage of viable cells with low-DHE staining (Figure 3A).
Following longer Dex treatment with Caspase inhibition (24 h),
the percentages of viable cells with abnormal mitochondria was
further increased (Figure 4C). Importantly, Lck-Casp9DN cells
fixed immediately following isolation (0 h) had a significant
proportion of cells with abnormal mitochondria (Figure 4C),
which also closely matched the percentage of freshly isolated
thymocytes with low-DHE staining (Figure 3C). TEM was also
applied in FL5 cells, an IL3-dependent pro-B lymphocytic cell
line. IL-3 deprivation combined with Caspase inhibition signifi-
cantly increased the average number of abnormal mitochondria
per cell and the percentage of viable cells with abnormal
mitochondria (Figure 4D). Again, the percentage of cells with
abnormal mitochondria was also comparable to the percentage of
cells with low-DHE staining (data not shown).
Caspase inhibition activates mitophagy in FL5 cells and
primary thymocytes
Following 24 hours of Dex treatment with Caspase inhibition, we
observed abnormal mitochondria engulfed within a double-mem-
brane vesicle that appeared very similar to an autophagosome and
consistent with activation of mitophagy (Figure 4A-right bottom). To
verify if Caspase inhibition activates mitophagy in lymphoid cells, IL-
3 deprived FL5-Neo-LC3-GFP cells were co-stained with Mito-
Tracker Red (MR) and examined with confocal microscopy. In the
absence of Caspase inhibition, MR staining did not significantly
overlap with LC3-GFP. However, in the presence of Q-VD-OPh,
MR staining colocalized with LC3-GFP, indicating the activation of
mitophagy in FL5-Neo-LC3-GFP cells (Figure 4E). p62/SQSTM is
an adaptor protein that binds to polyubiquitinated proteins and LC3
on the autophagosome membrane to target damaged organelles or
Figure 2. Casp9DN expression has no effect on thymic cellularity and proliferation in Lck-Bax38/1 mice. A) DNA content analysis was
performed on freshly isolated thymocytes from mice of the indicated genotypes between 8 and 10 weeks of age. Each symbol corresponds to the
percentage of cycling cells (%S/G2/M) observed from an individual mouse. The mean 6 SD of at least 6 mice per group is shown. B) Total thymic
cellularity from mice of the indicated genotypes between 8 and 10 weeks of age is shown. Each symbol corresponds to the total viable thymocytes
number observed from an individual mouse. The mean 6 SD of at least 6 mice per group is shown.
doi:10.1371/journal.pone.0019786.g002
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degradation [23]. To further confirm if mitophagy is specifically
activated under the condition of Caspase inhibition, IL-3 deprived
FL5 cells were stained with MR, immuno-stained with p62 antibody
with green fluorescence, and examined with confocal microscopy.
Those cells were also treated with Bafilomycin A1 to prevent p62
degradation and autophagic flux. FL5 cells over-expressing Bcl-2
were also examined. Overexpression of Bcl-2 is shown to prevent
MOMP under stress [24] and inhibit autophagy through Beclin 1
interaction [27,28]. Again, in the condition of Caspase inhibition,
MR staining significantly colocalized with the green fluorescence of
p62 whereas in the absence of Caspase inhibition or Bcl-2
overexpression, MR staining did not considerably overlap with the
green fluorescence of p62 (Figure 4F). Caspase inhibition had no
effect on p62 localization inthe absence of a celldeath signal (data not
shown). Furthermore, Pearson’s correlation coefficient (PCC, R(r))
was used as standard to measure colocalization between MR and the
green fluorescence of p62, indicating mitophagy. Caspase inhibition
significantly increased PCC compared to control or Bcl-2 cells
(Figure 4F). In sum, these results in FL5 cells and thymocytes
demonstrate that apoptotic activation combined with Caspase
inhibition results in abnormal mitochondria morphology and the
activation of mitophagy.
Lck-Casp9DN mice are not susceptible to thymic
lymphoma
To determine the effect of Casp9DN on cancer, lymphoma free
survival was examined in Lck-Casp9DN with or without crossing
with Lck-Bax38/1 transgenic mice, a strain known to develop
thymic lymphomas with a short latency and complete penetrance
[8]. Surprisingly, Lck-Casp9DN mice failed to promote oncogen-
esis either alone or when combined with Lck-Bax38/1 mice
(Figure 5). Just a single Lck-Casp9DN mouse had a thymic
lymphoma at 74 weeks of age, which was not statistically different
from the non-transgenic control group.
Beclin 1 Haploinsufficiency does not promote T-cell
lymphoma formation
The results above indicate that Casp9DN expression activates
autophagy but failed to accelerate rate of lymphoma development
in these models. Autophagy has recently been implicated as an
important tumor suppressor pathway based on studies in both
Figure 3. Casp9DN reduces ROS levels in primary thymocytes.
A) Representative histogram overlays of DHE stained viable thymocytes
is shown. All cells were treated with or without Dex as indicated.
Caspase activity was inhibited by either Casp9DN expression (red line,
Casp9DN) or Q-VD-OPh treatment (blue line, WT+QVD) and compared
to control cells (gray shaded, WT-wild type thymocytes). For the
histogram overlay graphs, the viability of thymocytes was as follows;
24 h culture without Dex: 46% (WT), 56% (Casp9DN), and 69%
(WT+QVD); 24 h culture with 1mM Dex: 7.5% (WT), 20% (Casp9DN),
and 42% (WT+QVD). Quantitation of the percentage of cells with low
DHE staining (gate shown in histograms) from the samples as indicated
is shown in the bottom panel. The mean + SD of at least duplicate mice
per group is shown. 1 p,0.05 versus the control. * p,0.01 versus the
control. B) Representative histogram overlays of the MitoSOX Red
stained viable thymocytes as indicated is shown. Data is representative
of at least 3 independent animals. C) Representative histogram overlays
of the DHE staining of the viable freshly isolated thymocytes from wild
type mice (gray shaded, WT) and Lck-Casp9DN mice (red line, C9DN) is
shown. The numbers are the percentage of cells found within the
indicated gate for each sample. Quantitation of % DHE-Low population
in freshly isolated thymocytes from mice of the indicated genotypes is
shown. The mean + SD of at least 4 mice per group is shown.* p,0.005.
doi:10.1371/journal.pone.0019786.g003
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mitochondrial structures (normal mitochondria marked with black arrows and abnormal mitochondria marked with yellow arrows) in isolated
thymocytes from mice of the indicated genotypes following the indicated treatment. One of examples of mitophagy showed that a mitochondrial
cluster was engulfed within double-membrane autophagosome in bottom-right image. Four images have the same magnification. Scale Bar
=0.2 mm. N=nucleus. B) Quantitation of the average number of normal and abnormal mitochondria per viable cell (left panel) and the percentages
of cells with at least 1 normal mitochondrion or with at least 1 abnormal mitochondrion (right panel) in isolated thymocytes from mice of indicated
genotypes following 4 h of the indicated treatment. C) Quantitation of the percentage of cells with at least 1 abnormal mitochondria in isolated
thymocytes from mice of the indicated genotypes following various times of Dex treatment. Table shows that no abnormal mitochondria were
observed in WT thymocytes following various treatments. In the WT thymocytes treated with 24 h of Dex, 5% of the cells were viable, so this sample
is not shown (@). WT thymocytes treated with 0 h of Q-VD-OPh were not available (NA). D) In FL5-Neo cells, quantitation of the average number of
normal and abnormal mitochondria per viable cell (left panel) and the percentages of viable cells with at least 1 normal mitochondrion or with at
least 1 abnormal mitochondrion (right panel) following 24 h of the indicated treatments. E) FL5-Neo cells transfected with LC3-GFP (green) were
stained with MitoTracker Red (red, MR) for mitochondria and TO-PRO-3 probe (blue) for nuclear counter staining following 48 h of the indicated
treatment. The viability of FL5 cells: 97% (+IL-3), 9% (-IL-3), and 66% (-IL-3+QVD). Colocalization of MR and LC3-GFP indicated mitophagy activation. F)
FL5 cells with the indicated expression were immuno-stained with p62 (green), MR (red) for mitochondria and TO-PRO-3 probe (blue) for nuclear
counter staining following 48 h of IL-3 deprivation and BafA (20 nM). Pearson’s correlation coefficient (PCC, R(r)) which statistically measures
colocalization of p62 and MR is shown in each image. Quantitation of PCC of the treated FL5 cells is shown. Each symbol corresponds to PCC of each
viable cell of the indicated cell lines. The mean 6 SD of at least 22 cells per cell line in each treatment is shown. ** p,0.0001.
doi:10.1371/journal.pone.0019786.g004
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of the autophagy pathway and has been shown to be a
haploinsufficient tumor suppressor [20]. Therefore, we hypothe-
size that Beclin 1 may play an important role in limiting tumor
formation in a Lck-Casp9DN transgenic model. We therefore
examined the effect of Beclin 1+/2 on tumor development in Lck-
Casp9DN, Lck-Bax1, and Lck-Bax38/1 transgenic mice. As
expected, thymocytes from Beclin 1+/2 mice had reduced Beclin
1 protein levels (Figure 6A). Tumor watch analysis of Lck-
Casp9DN mice for up to 90 weeks showed very low penetrance of
lymphoma with no significant difference between Beclin 1 wild
type and heterozygous mice (Figure 6B). To determine if Beclin 1
would be rate limiting in a model with high tumor penetrance, a
tumor watch was performed on Lck-Bax38/1 mice that were
either Beclin 1 wild type or heterozygous. Again, no significant
difference in tumor formation was observed between Beclin 1 wild
type and heterozygous mice (Figure 6C). Finally, to determine if
Beclin 1 would be rate limiting in a model with intermediate
latency and penetrance, a tumor watch was performed on Lck-
Bax1 mice that were either Beclin 1 wild type or heterozygous.
Again, Beclin 1 gene dosage had no significant effect on tumor
formation in this model (Figure 6D).
Beclin 1 gene dosage does not affect cell death or ROS
levels
Autophagy has been shown to either promote or inhibit cell
death. Relevant to cell death regulation, autophagy has been
shown to be required for survival in Bax/Bak double deficient cells
[29]. We therefore determined if Beclin 1 gene dosage affects cell
death in thymocytes with and without Caspase inhibition (Lck-
Casp9DN or Q-VD-OPh) following treatment with Dex. Al-
though Caspase inhibition again provided significant protection
from cell death, Beclin 1 gene dosage had no effect on cell death
under these conditions (Figure 7A). Consistent with this in vitro
result, Beclin 1 gene dosage had no effect on thymic cellularity and
proliferation in control, Lck-Casp9DN, Lck-Bax1, and Lck-
Bax38/1 mice (Figure 7B). To determine if Beclin 1 gene dosage
affects ROS levels, DHE and MitoSOX Red staining were
performed on either freshly isolated thymocytes or cells cultured in
Dex. Under all conditions, Beclin 1 gene dosage had no effect on
DHE and MitoSOX Red staining (Figure 7C). To determine if
Beclin 1 gene dosage affected ROS in cells induced to undergo
mitophagy, thymocytes were treated with Dex in the presence of
Q-VD-OPh or Casp9DN expression and stained with DHE or
MitoSOX Red. Again, Beclin 1 gene dosage had no effect on ROS
levels under these conditions (Figure 7D). These results demon-
strate that Beclin 1 is not rate limiting in Casp9DN-induced tumor
formation in these murine models and does not affect ROS
alterations under these various conditions.
Discussion
Caspase inhibition has been shown to block apoptosome
function and reduce apoptotic cell death [30,31]. Although
Caspase inhibition prevents apoptotic cell death, it does not
provide significant long-term clonogenic survival (Figure 1C)
[24,25], and most cells eventually die by Caspase-independent cell
death pathway. Previous studies show that short-term cell survival
with apoptosome inhibition is dependent upon energy supplied by
glycolysis [24,25]. Importantly, recent studies suggest that rare
cells that have undergone MOMP may retain proliferative
capability. For example, enforced GAPDH expression maintains
ATP levels, enhances autophagy and promotes clonogenic survival
[25]. More recently, it is shown that MOMP within a single cell is
sometime incomplete, leaving some mitochondria intact and
permitting clonogenic survival [32]. However, all those studies
were based on in vitro examinations. Whether cells can recover
from MOMP and whether this event would promote oncogenesis
in vivo is unclear.
There is conflicting data related to inhibition of Caspase-9 and/or
apoptosome function and cancer. For example, numerous studies of
human cancer have demonstrated that Apaf-1 or Caspase-9 are
commonly reduced in cancer [11,12,15]. However, mutations in
either Caspase-9 or Apaf-1 have not been commonly identified in
cancers [33,34]. Similarly, conflicting results have been reported
utilizing murine models. Apaf-1 or Caspase-9 deficient mouse
embryonic fibroblasts cooperated with myc to promote oncogenic
transformation in nude mice [31]. However, in a myc-induced
lymphoma model, Caspase-9 or Apaf-1 deficiency had no effect on
Figure 5. Casp9DN expression does not promote lymphoma formation in Lck-Bax38/1 transgenic mice. Kaplan-Meier analysis for
lymphoma free survival A) comparing wild type (black open square, N=8) and Lck-Casp9DN (green solid triangle, N=12) mice, and B) comparing
Lck-Bax38/1 (black open square, N=12) and Lck-Casp9DN x Lck-Bax38/1 (red solid triangle, N=11) mice. Those mice were followed for lymphoma-
free survival as described under materials and methods. P-value of analysis is shown. ND=not determinable without any events in the control group.
doi:10.1371/journal.pone.0019786.g005
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apoptosome are involved in oncogenesis remain unknown.
Here, we generated an in vivo model of Casp9DN expressed in
the T cell lineage and examined its effect on oncogenesis.
Similarity to our previous in vitro study [24], Casp9DN significantly
inhibited apoptosome function in thymocytes (Figure 1B). Follow-
ing in vitro Dex treatment, we observed a population of Casp9DN-
expressing thymocytes with abnormal mitochondria and reduced
DHE and MitoSOX Red oxidation. TEM images revealed that
Casp9DN cells with dramatically altered mitochondrial morphol-
ogy and apparent localization within autophagosomes consistent
with increased mitophagy. Importantly, about 5–10% of freshly
isolated thymocytes from Lck-Casp9DN mice displayed reduced
DHE oxidation indicative of altered mitochondrial function. TEM
studies of freshly isolated thymocytes from Lck-Casp9DN mice
confirmed that some of these cells had altered mitochondrial
morphology. These results demonstrate that thymocytes in vivo are
protected from MOMP-dependent death by Casp9DN. However,
Casp9DN expression had no effect on thymic cellularity and
proliferation in vivo suggesting that cellular homeostasis is not
significantly altered in these mice. However, since oncogenesis is
thought to occur following multiple mutations within a single cell,
we proceeded to determine whether Casp9DN expression alone or
in combination with other proven oncogenic models would
promote oncogenesis. Over the first year of the tumor watch,
none of the control or Casp9DN animals developed evidence of
lymphoma. When the study was terminated and post mortem
necropsies performed, one Casp9DN animal that was nearly 1.5
years-old had developed a thymic lymphoma. It is possible that
additional thymic tumors would have been observed had the study
continued for the entire life of the mice. However, it is clear that
Casp9DN expression in the thymus of mice did not increase
thymic lymphoma formation in the first year of life.
In addition, we also determined whether Casp9DN would
promote oncogenesis in two other cancer-prone strains. Lck-
Bax38/1 mice were examined since lymphoma formation is
thought has been shown to be regulated in part by mitochondrial
derived pro-oxidants [35]. In addition, since mitophagy was
activated in Lck-Casp9DN mice, we also examined oncogenesis in
tumor-prone mice with impaired autophagy (Beclin 1+/2).
Surprisingly, Casp9DN had no effect on the rate of tumor
development in either of these models. These data extend the
previous studies that have demonstrated that Caspase-9 or Apaf-1
deficiency failed to promote oncogenesis in a myc-induced
lymphoma model [16,17]. We conclude that inhibition of the
apoptosome does not significantly promote lymphoma formation
in mice. These studies have not addressed whether Casp9DN
would promote epithelial tumor formation. Given that many
known oncogenes and tumor suppressor genes regulate T-cell
lymphoma in mice, we predict that inhibition of the apoptosome
will not significantly alter tumor formation in epithelial cells. In
Figure 6. Beclin 1+/2 does not accelerate lymphoma formation.
A) Primary thymocytes were isolated from mice of the indicated
genotypes. Immunoblots for Beclin 1, and actin as a loading control are
shown. The ratio of Beclin 1 to actin for each mouse is shown below the
immunoblots. Kaplan-Meier analysis for lymphoma free survival B)
comparing Beclin 1+/+ x Lck-Casp9DN (black open square, N=12) and
Beclin 1+/2 x Lck-Casp9DN (green solid diamond, N=14) mice, C)
comparing Beclin 1+/+ x Lck-Bax38/1 (black open square, N=11) and
Beclin 1+/2 x Lck-Bax38/1 (green solid diamond, N=13) mice, and D)
comparing Beclin 1+/+ x Lck-Bax1 (black open square, N=15) and
Beclin 1+/2 x Lck-Bax1 (green solid diamond, N=12) mice is shown.
Those mice were followed for lymphoma-free survival as described
under materials and methods. P-value of analysis is shown.
doi:10.1371/journal.pone.0019786.g006
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neuronal tumors is not addressed. Importantly, previous studies
demonstrate that inhibition of Caspases and/or the apoptosome
provides long-term protection from death of neuronal cells [30].
This is true in vivo in a stroke model [36] as well as in vitro models
utilizing primary cultures [37,38]. While other studies would be
required to definitively address the role of the apoptosome in
neuronal tumor formation, one study failed to find loss of function
mutations in Caspase-9 in neuroblastoma [39].
Beclin 1 is an essential autophagy gene for early embryonic
development and reported to be a haploinsufficient tumor suppresser
gene based on genetic studies in human cancer samples as well as
gene heterozygous deletion studies in mice [18–20]. Recently, in vitro
studies suggest that loss of one allele of Beclin 1 leads to elevated ROS
levels, increases DNA damage and chromosomal instability, and
promotes tumor growth in nude mice [21–23]. However, the cell
lines used in these studies were genetically manipulated to inactivate
cell cycle checkpoints and to block apoptosis. Thus whether Beclin 1
haploinsufficiency would cooperate with other pro-oncogenic
pathways and promote oncogenesis in an intact organism has not
yet been investigated. Since ROS and chromosomal instability have
been implicated in oncogenesis in Lck-Bax38/1 mice, we examined
whether Beclin 1 gene dosage would affect tumorigenesis in this
model.Surprisingly,Beclin1+/2did not significantlypromote T-cell
lymphoma formation in Lck-Bax38/1 mice. It is possible the Beclin
1+/2 had no affect in Lck-Bax38/1 mice due to the high penetrance
and rapid tumor development in these mice. Therefore, we also
examined the effect of Beclin 1 gene dosage in Lck-Bax1 mice, which
develop lymphoma with only about 50% penetrance at one year.
Again, our results show that Beclin 1+/2 did not affect lymphoma
formation in Lck-Bax1 mice. Finally, we examined whether Beclin
1+/2 would cooperate with Casp9DN to promote oncogenesis.
Again, over the 90 weeks of the study, no difference in lymphoma free
survival was observed in the Beclin 1+/2 mice. These results are
consistent in the previous Beclin 1+/2 studies in which tumor
development was determined only after necropsy. In our study, we
only examined the mice for overt thymic lymphomas as this was the
site of expression of Casp9DN. Tumor formation in other organs was
not systematically determined. Again Beclin 1 gene dosage had no
effect on tumor formation under these conditions. In addition to
tumorformation,wealsodirectlyexaminedtheeffectofBeclin1gene
dosage on ROS levels. Beclin 1 gene dosage did not affect the ROS
levels either in directly isolated primary thymocytes or after 24 hours
of in vitro Dex treatment. Interestingly, Beclin 1 gene dosage had no
Figure 7. Beclin 1+/2 has no effect on cell death, proliferation
and ROS levels in thymocytes. A) Isolated thymocytes from mice of
the indicated genotypes were treated with Dex (1mM), using Q-VD-OPh
(50 mM) as positive control for Caspase inhibition. Viability was determined
over time. The means 6 SD ofat least 2 miceper groupare shown. B) DNA
content analysis of thymocytes (top panel) and thymic cellularity (lower
panel) were performed on freshly isolated thymocytes from mice of the
indicated genotypes between 8 and 12 weeks of age. Each symbol
corresponds to the percentage of cycling cells (%S/G2/M) and the total
viable thymocytes observed from an individual mouse. The mean 6 SD of
each group is shown. C) Representative histograms overlays of DHE and
MitoSOX Red staining of the viable thymocytes isolated from Beclin 1+/+
(gray shaded) and Beclin 1+/2 (black line) mice following the indicated
treatment are shown. The viability of thymocytes following 24h of Dex
treatment: 7.3% (Beclin 1+/+) and 8.9% (Beclin 1+/2). These results are
representative of at least 3 independent experiments. D) Representative
histogram overlays of the DHE and MitoSOX Red staining of the viable
thymocytesisolatedfromBeclin 1+/+and Beclin 1+/2mice are shown. For
each graph, Beclin 1+/+ cells without caspase inhibition (gray shaded),
Beclin 1+/+ cells with caspase inhibition (black line) and Beclin 1+/2 cells
with caspaseinhibition (greenline)eitherby Casp9DNexpressionor Q-VD-
OPhtreatment are shown. The viabilityof thymocytes following 24hof Dex
treatmentwas as follows: 7.3% (Beclin 1+/+), 20% (Beclin 1+/+ xC a s p 9 D N ) ,
and 22% (Beclin 1+/2 x Casp9DN), 42% (Beclin 1+/+ Q-VD-OPh), and 43%
(Beclin 1+/2 Q-VD-OPh).
doi:10.1371/journal.pone.0019786.g007
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thymocytes (data not shown). Finally, Beclin 1 levels did not alter
the reduced ROS levels observed in primary thymocytes following
either molecular or chemical inhibition of the apoptosome. In sum,
o u rd a t as u g g e s tt h a tB e c l i n1h a dn oe f f e c to nR O Sl e v e l si np r i m a r y
thymocytes under either basal or stressed conditions. These results
suggest that Beclin 1 is not a rate limiting tumor suppressor gene in
murine thymic lymphoma.
Materials and Methods
Mice
The Lck-Casp9DN construct was generated by ligation of the
Casp9DN fragment from polymerase chain reaction (PCR) with a
forward primer (59-GACTAGATCTCCATGGACGAGGCGG-
ACCGG-39) and reverse primer (59- GACTAGATCTTCATGA-
AGTTTTAAAAAACAGCT -39) of pIRES-GFP-Casp9DN (a gift
from Scott Lowe [17]) into the BamHI site of the Lck-hGH vector.
This construct contains an inactivating mutation in the active site
cysteine that results in inhibition of the endogenous enzyme due to
the multimeric nature of the apoptosome. The mice were ge-
nerated by the University of Iowa Transgenic Facility. In brief,
pronuclei from fertilized oocytes (B6/SJL F1 hybrid) were injected
with linearized DNA and the oocytes incubated overnight before
transplantation into the oviduct of pseudopregnant mice. Ten
independent lines were generated and the two lines showing the
highest level of expression were chosen for subsequent analysis.
The line with the highest level of expression (Line H) was used in
this study. Lck-Casp9DN transgenic mice were genotyped by PCR
using a forward Caspase-9 cDNA primer (59-GGCATACACC-
CTGGATTCGG -39 within exon 4 of Caspase-9) and a reverse
Caspase-9 cDNA primer (59-AGAGGATGACCACCACAAAG-
C-39, within exon 5 of Caspase-9). The primers produced a
270 bp fragment specific to transgene mice or a 520bp fragment in
non-transgenic mice after 35 cycles (94uC 61 min; 55uC 61 min;
and 72uC61.2 min). Lck-Casp9DN mice were backcrossed onto a
C57BL/6 background and crossed to Lck-Bax38/1 transgenic or
Beclin 1 +/- mice for tumor development studies.
Transgenic Lck-Bax mice were previously described and
genotyped by PCR method [8]. Lck-Bax38/1 are mice that
harbor two independent transgenic Bax constructs as previously
described [9]. Lck-Bax1 are mice that harbor one of two
independent transgenic Bax constructs as previously described
[9]. Beclin 1+/- mice were provided by Dr. Zhenyu Yue (Mount
Sinai School of Medicine, The Rockefeller University, NY), and
genotyped by PCR, using a forward primer (Neo: 59-
CGCCTTCTATCGCCTTCTTGACGAGTTCT-39) for Neo,
a forward primer (BCNKOT-2R; 59- GAGCTGGCTCCTGT-
GAGTATG-39), and a reverse primer (BCNKOT-1C: 59- TGG-
AGGGCAGTCCATACCCTGG-39) following Dr. Yue’s proto-
col [20]. Beclin 1+/- mice were backcrossed onto a C57BL/6
background and crossed to Lck-Bax1, and Lck-Bax38/1 trans-
genic mice for tumor development studies.
Tumor development studies
All mice were maintained in the University of Iowa animal
facility under approved protocols by the Institutional Animal Care
and Use Committee (IACUC). Mice of the appropriate genotypes
were mated to obtain sufficient cohorts of animals needed for the
tumor development studies. Littermate controls or controls from
the same mating pairs were used for all these studies. Upon entry
into the tumor development study, animals were examined weekly
for signs of illness or malignancy. Sick animals were monitored
more frequently and euthanized when necessary to prevent
unneeded suffering. All animals were monitored for up to 90
weeks and then sacrificed for necropsy. Animals that did not show
any evidence of lymphoma were censored from the analysis of
tumor free survival. When possible, necropsies were performed on
dead animals to determine if the animals had gross evidence of
lymphoma. Tumors were then confirmed by fixation with 10%
formalin and histological examination after H&E staining.
Cell culturing and viability
Single cells suspensions from thymi were prepared and cell
viability by Guava and Annexin V staining were performed as
described [24,40]. Murine FL5.12 hematopoietic prolymphocytic
B cells were maintained and deprived of IL-3 for apoptosis
induction as previously described [24]. A pan Caspase inhibitor,
quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]- methyl ke-
tone (Q-VD-OPh or QVD, from MP Biomedicals (#03OPH109-
03) or SM Biochemicals (#SMPH001)) was used as positive control
of Caspase inhibition (50 mM). Dexamethasone (#D1756, Sigma)
was used to induce cell death in thymocytes (1 mM). Bafibafilomycin
A1 (#B1080, LC Laboratories, 20nM) was used to prevent
maturation of autophagic vacuoles by inhibiting fusion between
autophagosomes and lysosomes.
Transfection of FL5 cells with LC3-GFP
FL5-Neo-LC3-GFP cells were generated using a HIV based
lentiviral system with the pTZV3 plasmid containing the genes for
LC3-GFP and hygromycin resistance as previously described [41].
Initially HEK 293T cells were transfected with Effectene transfection
kit (#301425, Qiagen) with the target plasmid pTZV3 Hygro-LC3-
GFP. At 18 h post-transfection virus particles were harvested from
the HEK 293T cells by collecting the media and filtering with a 0.22
mm syringe filter (Millipore). This collected media was then used to
infect the FL5-Neo cells by direct addition to these cells. This
transduction procedure was then repeated 4-5 times over a 3-day
period. Cells expressing LC3-GFP were selected with 1 mg/mL
hygromycin (#10687-010, Invitrogen) for 10 days in culture.
Immunoblot analysis
Lysates prepared from thymocytes were made in triton buffer
(1% triton X-100 in Versene with 20 mM Tris-HCl, pH=7.5)
supplemented with a protease inhibitor cocktail (#P8340, Sigma),
phosphatase inhibitor I and II (#P2850 and #P5726, Sigma), and
100 mM PMSF (#P7626, Sigma). Protein concentration was
determined using the DC Bradford assay kit (Bio-Rad). Protein
(20 mg) was electrophoresed in a 4% to 20% Tris-Glycine Gels
(EC60285BOX, Invitrogen), electrotransferred onto a nitrocellulose
membrane (Bio-Rad), and then stained with Ponceau S (Sigma) to
determine transfer efficiency. The membranes were then blocked in
5% dry fat-free milk in PBST (1(PBS and 0.05% Tween 20) for 1 h
at room temperature and probed with primary antibody overnight
at 4uC. Primary antibodies against Caspase-9 (#9504), Caspase-3
(#9665), Beclin 1 (#3738) were from Cell Signaling, and actin
(#A4700) and PARP (a gift from Joseph J. Cullen) p62/SQSTM1
(#P0067) (a gift from Martha M. Monick) was from Sigma, and
GAPDH (#ab9484) was from abcam. After incubation with the
primary antibody, the membranes were washed in PBST three
times and incubated with the following horseradish peroxidase-
conjugated secondary antibodies (1:10,000) in 5% dry fat-free milk
in PBST for 2 h at room temperature: goat anti-rabbit (#L42007,
Invitrogen), or goat anti-mouse (#sc-2005, Santa Cruz Biotehcnol-
ogy). After incubation, the membranes were washed three times in
PBST and the proteins identified by ECL (#NEL105001EA,
Perkin-Elmer) Densitometry analysis was performed with the UVP
Bioimaging System (UVP, Inc., Upland, CA, USA).
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Flow cytometry analysis was performed on a FACSCAlibur
instrument from Becton Dickenson within the University of Iowa
Department of Pathology flow cytometry facility. For DNA
content analysis, cells were stained with Krishan propidium iodide
buffer as previously described [24]. For DHE staining, cells were
pelleted and resuspended in PBS containing 5 mM pyruvate, 10
mM DHE (dihydroethidium, #D11347, Invitrogen) and 10 mM
antimycin A (#A8674, Sigma) treatment as a positive control.
Cells were then incubated for 20 min at 37uC. DHE-stained cells
were pelleted and resuspended in annexin V binding buffer with
annexin V-Cy5 (1:1000) (#K103-100, Biovision). Cells were
covered and kept on ice until analyzed on a FACSCalibur flow
cytometer. Only viable cells (annexin V-negative) were analyzed
for DHE fluorescence (FL2). For MitoSOX Red staining, cells
were pelleted and resuspended in RPMI media with 5 mM
MitoSOX Red (#M36008, Invitrogen) in PBS, and 10 mM
antimycin A treatment as a positive control. Cells were then
incubated for 10 min at 37uC. MitoSOX Red-stained cells were
pelleted and stained with annexin V-Cy5 as described above. Cells
were covered and kept on ice until analyzed on a FACSCalibur
flow cytometer. Only viable cells (annexin V-negative) were
analyzed for MitoSOX Red fluorescence (FL2).
Microscopic Analysis
All microscopic analysis was performed within the Central
Microscopy Research Facility at the University of Iowa. For
mitochondrial morphology (TEM), cells were fixed with 2.5%
glutaraldehyde in 0.1 M sodium cacodylate (pH=7.2) and stored
at 4uC until embedding. Cells were post-fixed with 1% osmium
tetroxide with 1.5% potassium ferrocyanide in 0.1 M sodium
cacodylate (pH=7.2), and then were followed by an increasing
gradient dehydration step using ethanol. Cells were then
embedded in Spurr low viscosity embedding medium (Ladd
Research) and ultra-thin (90 nM) sections were placed on
uncoated copper grids, and stained with 0.2% lead citrate and
1% uranyl acetate. Images were examined with a JEM-1230
electron microscope (JEOL, Central Microscopy Research
Facilities, The University of Iowa) at 100 kV. For quantitation
of mitochondria, the data obtained from a minimum of 25
independent viable cells was averaged (mean 6SD).
For colocalization of mitochondria and LC3-GFP, FL5-Neo-
LC3-GFP cells were spun down and resuspended with Mitotracker
Red (#M7512, Molecular Probe) in RPMI media (300 nM) for
20 min. Next, cells were washed with PBS twice and resuspended
in PBS. Cells were spun onto microscope slides using a cytospin
(Cytospin 2, Shandon) with 6006g for 5 min, and were fixed by
4% paraformaldehyde in PBS for 30 min. The slides were then
washed 4-5 time with PBS. Cells were nuclear counter stained by
TO-PRO-3 (1:2000 in PBS) for 5 min in the dark. TO-PRO-3
was then removed by wicking away with a paper towel and the
coverslips were then mounted onto a slide with 30 mL VECTA-
SHIELD Mounting Medium (#H-1000, Vector Laboratories).
Then extra liquid was removed from the coverslip by tilting the
slide and wicking away with a paper towel. For colocalization of
mitochondria and p62, the cells were stained with Mitotrakcer
Red, fixed by 4% paraformaldehyde as described above, and
permeabilized for 10 min in 0.2% Triton X-100 in PBS. The
slides were then blocked in blocking buffer (PBS, 5% normal goat
serum) for 1 h at room temperature. The slides were then
incubated overnight at 4uC with polyclonal rabbit anti-p62/
SQSTM1 antibody (1:2000, #P0067, Sigma). The slides were
then washed extensively in PBS. The slides were then incubated
with Alexa-488-conjugated goat anti-rabbit immunoglobulin
(1:1000) in PBS for 1h at room temperature. Cells were nuclear
counter stained by TO-PRO-3 and the coverslips were then
mounted onto a slide with VECTASHIELD Mounting Medium
as describe above. The samples were imaged with a Bio-Rad
MRC 1024 confocal microscope, equipped with a Kr/Ar laser.
The LC3-GFP and MitoTracker Red (MR) fluorescence was
excited using the 488 nm laser, whereas TO-PRO-3 was excited
with the 647 nm laser. For image acquisition, a Bio-Rad MRC
1024 confocal microscope (Central Microscopy Research Facili-
ties, The University of Iowa) equipped with filters for Alexa-488,
Alexa-568, and TO-PRO-3 was employed. Final images were
prepared using Image J Software. Images were acquired and
analyzed with identical settings. Colocalization analysis of
Mitotracker Red and green fluorescence of p62 was processed
using LaserSharp 2000 software (Central Microscopy Research
Facilities, The University of Iowa). The whole area of each live cell
with complete nuclear counter staining was margined as region of
interest (ROI) and applied to colocalization analysis with the
threshold setting in channel 1 (red) and channel 2 (green).
Pearson’s correlation coefficient (PCC) was used to measure the
colocalization of Mitotracker Red and green fluorescence of p62.
Statistical analysis
Statistical analysis was performed with the StatView Program
(SAS Institute Inc.) using Kaplan-Meier cumulative survival to
determine if the differences in survival were significant between
each of the indicated groups. A two-tailed Student t test assuming
unequal variance was used to compare differences in cellularity,
cell viability, proliferation rate, DHE-Low population, PCC
analysis and normalized protein expression between groups.
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